简介: |
报告摘要：Many human solid tumors are immune suppressive leading to a poor response to immune therapy such as the checkpoint inhibitors. We have discovered that tumor associated fibroblasts, like tumor cells, over-express the sigma receptor which can be targeted with aminoethylanisamide as a ligand. Nanoparticles modified with AEAA are taken up by these cells with high efficiency. With additional designs for endosome escape and nuclear entry, plasmid DNA can be readily delivered to the tumor and be expressed locally and transiently. We have also designed fusion proteins that contain a high affinity binding domain, i.e. traps, for several chemo/cytokines and receptors. Nanoparticle delivery of the trap plasmid DNA to the tumor in several different orthotopic tumor models significantly remodeled the immune microenvironment. Trap therapy alone, or together with a checkpoint inhibitor, resulted in prolonged tumor growth inhibition and progression free survival of the host. Data will be presented for pancreatic, breast, colorectal cancers and melanoma.
报告人简介：Leaf Huang, Ph.D. is the Fred Eshelman Distinguished Professor, Division of Pharmacoengineering and Molecular Pharmaceutics in the Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. Dr. Huang’s research has been in the area of gene therapy and targeted drug delivery. He has pioneered the liposome non-viral vector and has designed and manufactured the cationic lipid vector for the first non-viral clinical trial in 1992. His current work centers on nanoparticle vectors for gene transfer in tumor and liver. He also continues research in establishing a ligand targeted delivery system for cDNA, mRNA, siRNA, proteins and peptides for tumor growth inhibition and for vaccines in treating cancer and infected diseases. He has authored or co-authored more than 500 papers with an H-index of 115. He is also the inventor or co-inventor of 21 US and foreign patents. In 2004, he received the Alec D. Bangham MD FRS Achievement Award, which is the highest honor in liposome research. He was the recipient of the 2013 Distinguished Pharmaceutical Scientist Award which is the highest scientific recognition of the American Association of Pharmaceutical Scientists. Dr. Huang has also co-founded 6 biotech start-ups in the past. |
